Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Cisplatin 3-Week vs 4-Week Regimen in NSCLC
NCT00489996Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jan 2003; status: completed.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00489996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00489996.